跳至主要内容
临床试验/NCT04614402
NCT04614402进行中(未招募)不适用

Transcatheter Repair of Tricuspid Regurgitation With Edwards PASCAL Transcatheter Valve Repair System: A European Prospective, Multicenter Post-Market Clinical Follow up

Edwards Lifesciences27 个研究点 分布在 4 个国家目标入组 300 人开始时间: 2021年1月15日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
300
试验地点
27
主要终点
Change in tricuspid regurgitation severity (scale of 0-5) by echocardiography

研究概览

简要总结

This is a postmarket clinical follow up study on the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System and the Edwards PASCAL Precision Transcatheter Valve Repair System in transcatheter tricuspid valve repair.

详细描述

The objectives of this clinical study are to collect data on the safety and effectiveness of the PASCAL System and PASCAL Precision System in improving TR, functional status, and quality of life in a post-market setting.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient is a candidate for transcatheter tricuspid valve repair as determined by a Heart Team
  • TR grade ≥3+ (5 grade classification)
  • Patient is eligible to receive the PASCAL device per the current approved indications for use

排除标准

  • Tricuspid valve anatomic contraindications, including previous tricuspid valve replacement
  • Severe aortic, mitral, and/or pulmonic valve stenosis and/or regurgitation
  • Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
  • Any patient considered to be part of a vulnerable population

结局指标

主要结局

Change in tricuspid regurgitation severity (scale of 0-5) by echocardiography

时间窗: Discharge: defined as discharge or 7 days post-procedure, whichever comes first

Reduction in TR severity as assessed by TEE pre and post-implant in the procedure room. TR severity compared to baseline will be assessed by TR grade at each follow-up interval.

Number of patients with major adverse events (MAE rates)

时间窗: 30 days

The primary safety endpoint is the proportion of patients with major adverse events (MAEs) at 30 days

次要结局

  • Volume overload assessed by serial measurements(baseline, 30 days, 6 months, 12 months, annually up to 5 years)
  • Functional class, functional status, and Quality of life as assessed(baseline, 30 days, 6 months, 12 months, annually up to 5 years)

研究者

发起方
Edwards Lifesciences
申办方类型
Industry
责任方
Sponsor

研究点 (27)

Loading locations...

相似试验

Transcatheter Repair of Tricuspid Regurgitation With... | 临床试验